loader
Please Wait
Applying Filters...

Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Momelotinib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Momelotinib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass

    Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.

    One Pharma aims to be one of the leading generic companies in Europe.

    2D Structure
    1. Also known as: Cyt387, 1056634-68-4, Cyt-387, Cyt 387, N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide, Cyt 11387
    Molecular Formula
    C23H22N6O2
    Molecular Weight
    414.5  g/mol
    InChI Key
    ZVHNDZWQTBEVRY-UHFFFAOYSA-N
    FDA UNII
    6O01GMS00P
    Momelotinib is an orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity. JAK1/2 inhibitor CYT387 competes with JAK1/2 for ATP binding, which may result in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and so the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
    2.1.2 InChI
    InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
    2.1.3 InChI Key
    ZVHNDZWQTBEVRY-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
    2.2 Other Identifiers
    2.2.1 UNII
    6O01GMS00P
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cyt 387

    2. Cyt-387

    3. Cyt387

    4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

    2.3.2 Depositor-Supplied Synonyms

    1. Cyt387

    2. 1056634-68-4

    3. Cyt-387

    4. Cyt 387

    5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide

    6. Cyt 11387

    7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide

    8. Gs-0387

    9. Momelotinib (cyt387)

    10. Cyt-11387

    11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide

    12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide

    13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

    14. 6o01gms00p

    15. Chembl1078178

    16. Cyt-0387

    17. Cyt11387

    18. Mfcd16038899

    19. Lm-1149

    20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide

    21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide

    22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-

    23. Momelotinib [usan]

    24. Momelotinib [usan:inn]

    25. Momelotinibum

    26. Unii-6o01gms00p

    27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

    28. C87

    29. Momelotinib [inn]

    30. Momelotinib (usan/inn)

    31. Momelotinib [who-dd]

    32. Mls006011154

    33. Gtpl7791

    34. Schembl2237234

    35. Chebi:91407

    36. Ex-a260

    37. Dtxsid801026049

    38. Hms3244k19

    39. Hms3244k20

    40. Hms3244l19

    41. Hms3295i01

    42. Hms3655d12

    43. Hms3744c15

    44. Bcp02328

    45. Cyt387, Cyt11387

    46. Cyt387,cyt 11387

    47. Momelotinib (cyt387,cyt-387)

    48. Bdbm50311017

    49. Nsc767598

    50. Nsc800800

    51. S2219

    52. Zinc43199890

    53. Akos015904624

    54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide

    55. Bcp9000570

    56. Ccg-264946

    57. Cs-0053

    58. Db11763

    59. Nsc-767598

    60. Nsc-800800

    61. Sb14602

    62. Ncgc00244257-01

    63. Ncgc00244257-08

    64. Ac-23162

    65. As-19389

    66. Hy-10961

    67. Smr004702928

    68. Sy060668

    69. Ft-0755949

    70. Sw219679-1

    71. D10315

    72. A857769

    73. Q252602

    74. J-001468

    75. J-523159

    76. Brd-k87737963-001-01-1

    77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide

    78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide

    79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide

    80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide

    81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-

    82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387

    83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide

    2.4 Create Date
    2008-12-01
    3 Chemical and Physical Properties
    Molecular Weight 414.5 g/mol
    Molecular Formula C23H22N6O2
    XLogP32.6
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count6
    Exact Mass414.18042397 g/mol
    Monoisotopic Mass414.18042397 g/mol
    Topological Polar Surface Area103 Ų
    Heavy Atom Count31
    Formal Charge0
    Complexity615
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of myelofibrosis

    Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

    Post Enquiry
    POST ENQUIRY